Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Cantor Fitzgerald
Federal Trade Commission
Express Scripts
Daiichi Sankyo
Teva
Accenture
Mallinckrodt
US Department of Justice

Generated: February 21, 2018

DrugPatentWatch Database Preview

Naproxen - Generic Drug Details

« Back to Dashboard

What are the generic sources for naproxen and what is the scope of naproxen patent protection?

Naproxen
is the generic ingredient in eleven branded drugs marketed by Atnahs Pharma Us, West-ward Pharms Int, Actavis Elizabeth, Fosun Pharma, Invagen Pharms, Mylan Pharms Inc, Pliva, Teva, Amneal Pharms Ny, Aurobindo Pharma Ltd, Chartwell Molecules, Dava Pharms Inc, Glenmark Generics, Hamilton Pharms, Hikma Intl Pharms, Ivax Sub Teva Pharms, Marksans Pharma, Mylan, Perrigo R And D, Purepac Pharm, Roxane, Teva Pharms, Watson Labs, Watson Labs Teva, Zydus Pharms Usa, Bionpharma Inc, Alvogen Malta, Actavis Labs Fl Inc, Bayer, Able, Contract Pharmacal, Dr Reddys Labs Inc, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Granules India, Hikma, Lnk Intl Inc, Perrigo, Sandoz, Sun Pharm Inds Ltd, and Pernix Ireland Ltd, and is included in seventy-one NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are forty-two drug master file entries for naproxen. Seventy-three suppliers are listed for this compound. There is one tentative approval for this compound.
Pharmacology for naproxen
Medical Subject Heading (MeSH) Categories for naproxen
Tentative approvals for NAPROXEN
Applicant Application No. Strength Dosage Form
➤ Sign Up➤ Sign Up250MGTABLET;ORAL
➤ Sign Up➤ Sign Up500MGTABLET;ORAL
➤ Sign Up➤ Sign Up375MGTABLET;ORAL

US Patents and Regulatory Information for naproxen

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074495-001 Dec 5, 1994 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Atnahs Pharma Us ANAPROX naproxen sodium TABLET;ORAL 018164-001 Approved Prior to Jan 1, 1982 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Perrigo R And D NAPROXEN naproxen TABLET;ORAL 077339-003 Apr 27, 2005 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Actavis Labs Fl Inc NAPROXEN SODIUM naproxen sodium TABLET, EXTENDED RELEASE;ORAL 075416-003 Aug 11, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Hikma Intl Pharms NAPROXEN naproxen TABLET;ORAL 076494-001 Jan 14, 2004 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Bayer ALEVE-D SINUS & COLD naproxen sodium; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 021076-001 Nov 29, 1999 OTC Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Invagen Pharms NAPROXEN naproxen TABLET;ORAL 091305-001 Aug 24, 2011 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Able NAPROXEN SODIUM naproxen sodium TABLET;ORAL 076544-001 Aug 22, 2003 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Pernix Ireland Ltd TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-002 May 14, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Pernix Ireland Ltd TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-001 Apr 15, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for naproxen

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-004 Apr 15, 1982 ➤ Sign Up ➤ Sign Up
Atnahs Pharma Us NAPROSYN naproxen SUSPENSION;ORAL 018965-001 Mar 23, 1987 ➤ Sign Up ➤ Sign Up
Atnahs Pharma Us NAPROSYN naproxen SUSPENSION;ORAL 018965-001 Mar 23, 1987 ➤ Sign Up ➤ Sign Up
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-003 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-004 Apr 15, 1982 ➤ Sign Up ➤ Sign Up
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-002 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-002 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-003 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-002 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-002 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Boehringer Ingelheim
Mallinckrodt
Cipla
Cerilliant
Medtronic
Healthtrust
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot